Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17917233 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | Non-Final OA | The Regents of the University of California |
| 18279004 | LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS | Non-Final OA | Ohio State Innovation Foundation |
| 18102623 | GOLD MOLECULAR CLUSTERS AND METHODS OF USING SAME FOR NEAR-INFRARED IMAGING | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18041811 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | Final Rejection | UNIVERSITY OF CONNECTICUT |
| 18540656 | NEUROPROTECTIVE LIPOSOME COMPOSITIONS AND METHODS FOR TREATMENT OF STROKE | Non-Final OA | The Board of Regents of The University of Texas System |
| 18690391 | MAKEUP KIT COMPRISING AN AQUEOUS MAKEUP COMPOSITION AND A CONTINUOUS OILY-PHASE FIXING COMPOSITION WITH A HYDROPHOBIC FILM-FORMING POLYMER | Non-Final OA | L'OREAL |
| 17620946 | ANHYDROUS COMPOSITION COMPRISING AT LEAST ONE AMINO SILICONE, AT LEAST ONE ALKOXYSILANE AND AT LEAST ONE COLORING AGENT | Non-Final OA | L'OREAL |
| 17610334 | INSTRINSICALLY LUBRICATING DRUG-LOADED HYDROGELS FOR USE AS PROPHYLACTIC MEDICAL DEVICES | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18227049 | QUANTITATIVE NIR REFERENCE AND EXPOSURE | Non-Final OA | ARTHREX, INC. |
| 17549959 | Composition For The Remineralization Of Teeth | Final Rejection | Ivoclar Vivadent AG |
| 18024459 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | Non-Final OA | Shionogi & Co., Ltd. |
| 18314688 | IMMUNOTHERAPY OF SKIN CANCER USING MPLA-LOADED HPG NANOPARTICLES | Final Rejection | Yale University |
| 18278750 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Non-Final OA | Bayer Aktiengesellschaft |
| 18264347 | PARTICLES FUNCTIONALIZED WITH THERAPEUTIC RADIOISOTOPES AND METHODS OF MAKING AND USE THEREOF | Non-Final OA | University of Virginia Patent Foundation |
| 18698130 | VERATRALDEHYDE, PIPERONYL ALCOHOL, ETHYL 2-AMINO BENZOATE, ISOAMYL CINNAMATE, OR DIETHYL MALONATE AS FOOD ADDITIVES WITH ANTI-INFLAMMATORY PROPERTIES | Non-Final OA | NATIONAL UNIVERSITY OF IRELAND, MAYNOOTH |
| 17801777 | CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME | Non-Final OA | The University of British Columbia |
| 18612062 | KITS FOR PREPARING A REACTIVE GRAFT MATERIAL AND INJECTING THE GRAFT MATERIAL INTO A PATIENT | Non-Final OA | Agnovos Healthcare, LLC |
| 18608350 | INJECTABLE COMPOSITIONS OF TRITERPENOID ANTIFUNGALS ENCAPSULATED IN LIPOSOMES | Non-Final OA | Scynexis, Inc. |
| 18691121 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFAlpha ANTIBODY | Non-Final OA | APROGEN Inc. |
| 18683531 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18575019 | COMPOSITIONS FOR DELIVERY OF MRNA | Non-Final OA | TRANSLATE BIO, INC. |
| 18292042 | METHODS OF TREATING COPPER METABOLISM-ASSOCIATED DISEASES OR DISORDERS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18291721 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | Non-Final OA | SACHEM, INC. |
| 18579054 | COMPOSITIONS COMPRISING PROANTHOCYANIDINS AND ZINC FOR TREATING AND/OR PREVENTING INFLAMMATION | Final Rejection | ANIMORA INC. |
| 17751959 | INHIBITION OF UNDESIRED SENSORY EFFECTS BY THE COMPOUND CAMPHOR | Non-Final OA | Philip Morris USA Inc. |
| 18250942 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | Final Rejection | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY |
| 18372339 | COMBINATION THERAPY FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE | Final Rejection | Insmed Incorporated |
| 18467343 | Methods of Treatment With an Iboga Alkaloid | Non-Final OA | Soneira Inc., P.B.C. |
| 17919053 | IMPROVED IMMUNE RESPONSE AND DECREASED IMMUNOPARALYSIS WITH IMMUNOMODULATING TREATMENT | Non-Final OA | CYTOSORBENTS, INC. |
| 18280113 | COPPER HISTIDINATE COMPOSITIONS AND USES THEREOF | Non-Final OA | Cyprium Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy